Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Press Release | December 18, 2023 at 13:05:00 EET
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease is pleased to announce that it has been selected to present at the Biotech Showcase taking place January 8-10, 2024 in San Francisco. The conference is being held in parallel to the J.P. Morgan 42nd Annual Healthcare Conference.
Presentation Details:
Date: Tuesday, January 09 - 2024
Time: 10:30AM (PST)
Track: Yosemite A (Ballroom Level)
Herantis’ CEO, Antti Vuolanto, and CSO, Henri Huttunen will also join one-on-one partnering and investor meetings in San Francisco from January 8-12, 2024. For more information and to schedule a meeting, please contact us at ir@herantis.com.
About Biotech Showcase:
Biotech Showcase is a premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies, offering them a unique opportunity to showcase their innovations and engage one-to-one with investors and biopharmaceutical executives.
About J.P. Morgan Healthcare Conference:
This conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community in San Francisco during January 8-12, 2024.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com